Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1776

1.

Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.

Sheehan DV, McElroy SL, Harnett-Sheehan K, Keck PE Jr, Janavs J, Rogers J, Gonzalez R, Shivakumar G, Suppes T.

J Affect Disord. 2009 Jun;115(3):376-85. doi: 10.1016/j.jad.2008.10.005. Epub 2008 Nov 29.

PMID:
19042026
2.

Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient.

Sheehan DV, Harnett-Sheehan K, Hidalgo RB, Janavs J, McElroy SL, Amado D, Suppes T.

J Affect Disord. 2013 Feb 15;145(1):83-94. doi: 10.1016/j.jad.2012.07.016. Epub 2012 Aug 21.

PMID:
22920718
3.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
4.

Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review.

Gao K, Muzina D, Gajwani P, Calabrese JR.

J Clin Psychiatry. 2006 Sep;67(9):1327-40. Review.

PMID:
17017818
5.

Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study.

Brawman-Mintzer O, Knapp RG, Nietert PJ.

J Clin Psychiatry. 2005 Oct;66(10):1321-5.

PMID:
16259547
6.

Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol.

Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F.

Eur Neuropsychopharmacol. 2005 Jan;15(1):75-84.

PMID:
15572276
7.

An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder.

Hirschfeld RM, Eerdekens M, Kalali AH, Canuso CM, Khan AA, Karcher K, Palumbo JM.

Int Clin Psychopharmacol. 2006 Jan;21(1):11-20.

PMID:
16317312
8.

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.

Davidson JR, DuPont RL, Hedges D, Haskins JT.

J Clin Psychiatry. 1999 Aug;60(8):528-35.

PMID:
10485635
9.
10.

Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.

Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J; Deramciclane Dose-Finding Study Group.

Eur Neuropsychopharmacol. 2005 Dec;15(6):617-23. Epub 2005 Jun 9.

PMID:
15949921
11.

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.

Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK.

J Clin Psychiatry. 2001 May;62(5):350-7. Erratum in: J Clin Psychiatry 2001 Aug;62(8):658.

PMID:
11411817
12.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
13.

A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder.

Suppes T, McElroy SL, Sheehan DV, Hidalgo RB, Cosgrove VE, Gwizdowski IS, Feldman NS.

J Clin Psychiatry. 2014 Jan;75(1):77-84. doi: 10.4088/JCP.12m08297.

PMID:
24345758
14.

Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials.

Weisler RH, Hirschfeld R, Cutler AJ, Gazda T, Ketter TA, Keck PE, Swann A, Kalali A; SPD417 Study Group.

CNS Drugs. 2006;20(3):219-31.

PMID:
16529527
15.

An open-label trial of risperidone augmentation for refractory anxiety disorders.

Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH.

J Clin Psychiatry. 2006 Mar;67(3):381-5.

PMID:
16649823
16.
17.

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR; BOLDER II Study Group.

J Clin Psychopharmacol. 2006 Dec;26(6):600-9. Erratum in: J Clin Psychopharmacol. 2007 Feb;27(1):51.

PMID:
17110817
18.

Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.

Haas M, Delbello MP, Pandina G, Kushner S, Van Hove I, Augustyns I, Quiroz J, Kusumakar V.

Bipolar Disord. 2009 Nov;11(7):687-700. doi: 10.1111/j.1399-5618.2009.00750.x.

PMID:
19839994
19.

A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder.

Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjödin I, Penttinen JT, Pedersen T, Lehto HJ.

J Clin Psychiatry. 1998 Oct;59(10):528-34.

PMID:
9818634
20.

Supplemental Content

Support Center